Search research articles
Contact Us
Filters
Showing results (171-180 of 205) with videos related to
Page
of 21
Sort By:
Oncotarget
|
August 7, 2019
Fibroblast-derived Gremlin1 localises to epithelial cells at the base of the intestinal crypt
Louise R Dutton, Owen P Hoare, Amy M B McCorry, et al.
Oncotarget
|
July 19, 2016
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Julie N Graff, Joshi J Alumkal, Charles G Drake, et al.
Breast Cancer Research : BCR
|
January 8, 2021
Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer
Katherine Sanchez, Isaac Kim, Brie Chun, et al.
Journal for Immunotherapy of Cancer
|
May 22, 2025
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering
Nisha Holay, Rashi Yadav, Sae Jeong Ahn, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
June 1, 2023
Computed cardiopulmonography and the idealized lung clearance index, iLCI<sub>2.5</sub>, in early-stage cystic fibrosis
Dominic Sandhu, Jennifer L Redmond, Nicholas M J Smith, et al.
Chest
|
February 12, 2024
Computed Cardiopulmonography for the Detection of Early Smoking-Related Changes in the Lungs of Young Individuals Who Smoke
Jennifer L Redmond, Fiona Kendall, Nicholas M J Smith, et al.
Molecular Cancer Research : MCR
|
March 18, 2022
Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity
Mia Han, Bianca Nguyen, Jack Y Lee, et al.
Cell Reports
|
June 17, 2014
ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer
Sandra Van Schaeybroeck, Murugan Kalimutho, Philip D Dunne, et al.
Journal for Immunotherapy of Cancer
|
July 4, 2020
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
Julie N Graff, Tomasz M Beer, Joshi J Alumkal, et al.
Science Translational Medicine
|
April 9, 2025
The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming
Annah S Rolig, Xiyu Peng, Elizabeth R Sturgill, et al.
Page
of 21
Search research articles
Search
Showing results (171-180 of 205) with videos related to
Sort By:
Page
of 21
Oncotarget
|
August 7, 2019
Fibroblast-derived Gremlin1 localises to epithelial cells at the base of the intestinal crypt
Louise R Dutton, Owen P Hoare, Amy M B McCorry, et al.
Oncotarget
|
July 19, 2016
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Julie N Graff, Joshi J Alumkal, Charles G Drake, et al.
Breast Cancer Research : BCR
|
January 8, 2021
Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer
Katherine Sanchez, Isaac Kim, Brie Chun, et al.
Journal for Immunotherapy of Cancer
|
May 22, 2025
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering
Nisha Holay, Rashi Yadav, Sae Jeong Ahn, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
June 1, 2023
Computed cardiopulmonography and the idealized lung clearance index, iLCI<sub>2.5</sub>, in early-stage cystic fibrosis
Dominic Sandhu, Jennifer L Redmond, Nicholas M J Smith, et al.
Chest
|
February 12, 2024
Computed Cardiopulmonography for the Detection of Early Smoking-Related Changes in the Lungs of Young Individuals Who Smoke
Jennifer L Redmond, Fiona Kendall, Nicholas M J Smith, et al.
Molecular Cancer Research : MCR
|
March 18, 2022
Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity
Mia Han, Bianca Nguyen, Jack Y Lee, et al.
Cell Reports
|
June 17, 2014
ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer
Sandra Van Schaeybroeck, Murugan Kalimutho, Philip D Dunne, et al.
Journal for Immunotherapy of Cancer
|
July 4, 2020
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
Julie N Graff, Tomasz M Beer, Joshi J Alumkal, et al.
Science Translational Medicine
|
April 9, 2025
The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming
Annah S Rolig, Xiyu Peng, Elizabeth R Sturgill, et al.
Page
of 21